Literature DB >> 10215595

Resistance of small leucine-rich repeat proteoglycans to proteolytic degradation during interleukin-1-stimulated cartilage catabolism.

R Sztrolovics1, R J White, A R Poole, J S Mort, P J Roughley.   

Abstract

A bovine nasal-cartilage culture system has been utilized to analyse the catabolic events occurring in response to interleukin-1beta over a 14-day period. An early event following the start of interleukin-1 treatment was the release of glycosaminoglycan into the culture medium. This release was accompanied by the appearance in the tissue, and shortly thereafter also in the culture media, of a globular domain (G1)-containing aggrecan degradation product generated by the action of aggrecanase. Link protein was also released from the cartilage with a similar timeframe to that of the G1 fragment, although there was no evidence of its proteolytic degradation. By comparison with aggrecan, the small leucine-rich repeat proteoglycans decorin, biglycan and lumican showed a resistance to both proteolytic cleavage and release throughout the culture period. In contrast, fibromodulin exhibited a marked decrease in size after day 4, presumably due to proteolytic modification, but the major degradation product was retained throughout the culture period. Also in contrast with the early changes in the components of the proteoglycan aggregate, type II collagen did not display signs of extensive degradation until much later in the culture period. Collagen degradation products compatible with collagenase action first appeared in the medium by day 10 and increased thereafter. These data demonstrate that the leucine-rich repeat proteoglycans are resistant to proteolytic action during interleukin-1-stimulated cartilage catabolism, compared with aggrecan. This resistance and continued interaction with the surface of the collagen fibrils may help to stabilize the collagen fibrillar network and protect it from extensive proteolytic attack during the early phases of cartilage degeneration.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215595      PMCID: PMC1220192     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  39 in total

Review 1.  Proteoglycan-fibrillar collagen interactions.

Authors:  J E Scott
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

2.  Interaction of a 59-kDa connective tissue matrix protein with collagen I and collagen II.

Authors:  E Hedbom; D Heinegård
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157

3.  Production of hydrogen peroxide by rabbit articular chondrocytes. Enhancement by cytokines.

Authors:  M L Tiku; J B Liesch; F M Robertson
Journal:  J Immunol       Date:  1990-07-15       Impact factor: 5.422

4.  Interaction of biglycan with type I collagen.

Authors:  E Schönherr; P Witsch-Prehm; B Harrach; H Robenek; J Rauterberg; H Kresse
Journal:  J Biol Chem       Date:  1995-02-10       Impact factor: 5.157

5.  Interleukin-1 reversibly inhibits the synthesis of biglycan and decorin in intact articular cartilage in culture.

Authors:  H von den Hoff; M de Koning; J van Kampen; J van der Korst
Journal:  J Rheumatol       Date:  1995-08       Impact factor: 4.666

6.  Identification of a hyaluronic acid-binding protein that interferes with the preparation of high-buoyant-density proteoglycan aggregates from adult human articular cartilage.

Authors:  P J Roughley; R J White; A R Poole
Journal:  Biochem J       Date:  1985-10-01       Impact factor: 3.857

7.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis.

Authors:  L S Lohmander; L A Hoerrner; M W Lark
Journal:  Arthritis Rheum       Date:  1993-02

8.  Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro.

Authors:  A P Hollander; R M Atkins; D M Eastwood; P A Dieppe; C J Elson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.

Authors:  C E Hughes; B Caterson; A J Fosang; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

10.  The immunologic detection and characterization of cartilage proteoglycan degradation products in synovial fluids of patients with arthritis.

Authors:  J Witter; P J Roughley; C Webber; N Roberts; E Keystone; A R Poole
Journal:  Arthritis Rheum       Date:  1987-05
View more
  16 in total

1.  Catabolism of aggrecan, decorin and biglycan in tendon.

Authors:  S G Rees; C R Flannery; C B Little; C E Hughes; B Caterson; C M Dent
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

Review 2.  Pivotal role for decorin in angiogenesis.

Authors:  Hannu Järveläinen; Annele Sainio; Thomas N Wight
Journal:  Matrix Biol       Date:  2015-02-07       Impact factor: 11.583

Review 3.  Biochemical composition and turnover of the extracellular matrix of the normal and degenerate intervertebral disc.

Authors:  Sarit Sara Sivan; Anthony J Hayes; Ellen Wachtel; Bruce Caterson; Yulia Merkher; Alice Maroudas; Sharon Brown; Sally Roberts
Journal:  Eur Spine J       Date:  2013-04-17       Impact factor: 3.134

4.  Age-related changes in the composition, the molecular stoichiometry and the stability of proteoglycan aggregates extracted from human articular cartilage.

Authors:  Terri Wells; Catherine Davidson; Matthias Mörgelin; Joseph L E Bird; Michael T Bayliss; Jayesh Dudhia
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

5.  A comparative evaluation of the small leucine-rich proteoglycans of pathological human intervertebral discs.

Authors:  Sharon Brown; James Melrose; Bruce Caterson; Peter Roughley; Stephen M Eisenstein; Sally Roberts
Journal:  Eur Spine J       Date:  2012-02-23       Impact factor: 3.134

Review 6.  Inflammation in intervertebral disc degeneration and regeneration.

Authors:  Maria Molinos; Catarina R Almeida; Joana Caldeira; Carla Cunha; Raquel M Gonçalves; Mário A Barbosa
Journal:  J R Soc Interface       Date:  2015-03-06       Impact factor: 4.118

7.  Expression and localization of the small proteoglycans decorin and biglycan in articular cartilage of Kashin-Beck disease and rats induced by T-2 toxin and selenium deficiency.

Authors:  Mengying Wang; Senhai Xue; Qian Fang; Meng Zhang; Ying He; Ying Zhang; Mikko J Lammi; Junling Cao; Jinghong Chen
Journal:  Glycoconj J       Date:  2019-09-02       Impact factor: 2.916

8.  Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis.

Authors:  Anuradha Krishnan; Xia Li; Winstonwhei-Yang Kao; Kimberly Viker; Kim Butters; Howard Masuoka; Bruce Knudsen; Gregory Gores; Michael Charlton
Journal:  Lab Invest       Date:  2012-09-24       Impact factor: 5.662

9.  Degradation of small leucine-rich repeat proteoglycans by matrix metalloprotease-13: identification of a new biglycan cleavage site.

Authors:  Jordi Monfort; Ginette Tardif; Pascal Reboul; François Mineau; Peter Roughley; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Arthritis Res Ther       Date:  2006-01-03       Impact factor: 5.156

Review 10.  Articular cartilage and changes in arthritis: noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage.

Authors:  P J Roughley
Journal:  Arthritis Res       Date:  2001-09-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.